Terguride in stable Parkinson's disease.

Terguride (TER) (2 mg/day) was compared with a placebo in 41 stable Parkinson's disease (PD) patients, so as to test its efficacy as an add-on treatment to spare levodopa (LD). After the 4th week of add-on treatment, LD was reduced by about 25%. The number of "stable" patients (--those with an increase of no more than 20% of the basal Columbia University Rating Scale (CURS) score--remaining after LD reduction was used to compare the two add-on treatments. Most patients, remained "stable" in spite of LD reduction, and no significant differences between the therapies were discovered; the CURS score decreased over time only in the TER group. Hence, TER was shown to be a drug that has DA-ergic properties but with minimal antiparkinsonian efficacy.
AuthorsE Martignoni, C Pacchetti, B Aufdembrinke, L Godi, G Albani, F Mancini, G Nappi
JournalFunctional neurology (Funct Neurol) 1995 May-Jun Vol. 10 Issue 3 Pg. 143-6 ISSN: 0393-5264 [Print] ITALY
PMID8557216 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Dopamine Agonists
  • Placebos
  • dironyl
  • Levodopa
  • Lisuride
  • Aged
  • Dopamine Agonists (administration & dosage, therapeutic use)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Levodopa (metabolism, therapeutic use)
  • Lisuride (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy)
  • Placebos

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: